Status:
COMPLETED
Drug Interaction Study of Famotidine and Atazanavir With Ritonavir in HIV-Infected Patients
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
HIV Infections
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this clinical research study is to assess the effect of Famotidine given twice daily on Atazanavir administered with Ritonavir in HIV-Infected subjects.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- HIV-infected male and female subjects between the ages of 18 to 65 years old with a BMI 18 to 35 kg/m²
- Prior to enrollment subjects must be currently receiving Atazanavir/Ritonavir plus at least 2 NRTIs, must have plasma HIV RNA \<400 copies/mL and have CD4 count \>200 cells/mm³
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00384904
Start Date
December 1 2006
End Date
December 1 2007
Last Update
February 5 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Garden State Infectious Disease Associates, Pa
Voorhees Township, New Jersey, United States, 08043
2
Unc Center For Aids Research
Chapel Hill, North Carolina, United States, 27599
3
Local Institution
Philadelphia, Pennsylvania, United States, 19104
4
Local Institution
London, Greater London, United Kingdom, SW10 9TH